Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD22 CAR-T in r/r B-ALL Children
NCT04340167Phase 2Completed
- Sponsor
- Beijing Boren Hospital
- Start
- May 2020
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Beijing Boren Hospital. Primary endpoint: Complete Remission Rate at 1 month. Started May 2020; status: completed.
02
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04340167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04340167.